Regulatory FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Big Molecule WatchOn April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.RegulatoryOphthalmologyRead full story pharminent April 15, 2026 Big Molecule Watch On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S. RegulatoryOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: Travere wins long-awaited approval for kidney disease drug Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
